Bisphosphonates: from bone anti-resorptive to anti-cancer drugs.

Mohammed Helmy Faris Shalayel1,2*, Saeed Ali Alsareii3, Abdulhadi Mohamed Elbashir4, Mohammed Ayed Huneif5

1Professor of Biochemistry and Dermatovenereologist, Nile College, Sudan
2College of Medicine, Najran University, Saudi Arabia
3Assistant Professor of Surgery, College of Medicine, Najran University, Saudi Arabia
4Assistant Professor of Pediatrics, College of Medicine, Najran University, Saudi Arabia

Abstract

Bisphosphonates, analogues of pyrophosphates, are utilized as efficient drugs against bone resorption in bone disorders like, osteoporosis, Paget's disease, multiple myeloma, cancer-induced hypercalcemia, and bony metastases. They suppress osteoclastic bone resorption by incorporating with hydroxyapatite binding sites on bony surfaces that undergo active resorption with due interference with various biochemical processes in bone-resorbing osteoclasts, impairing the ability of the osteoclasts and enhancing osteoclast apoptosis. The clinical utilization of bisphosphonates has dramatically expanded during the past 3 decades or more especially for osteoporosis to diminish the frequency of skeletal-related events in patients with breast cancer and myeloma. Some preclinical studies had reported that bisphosphonates exhibit direct and indirect anticancer activities in patients with early breast cancer or symptomatic multiple myeloma exhibiting disease-free survival and overall survival benefits. Moreover, some epidemiological and clinically applied studies concluded that current use of bisphosphonates in healthy postmenopausal women to manage osteoporosis was correlated with a 30% reduction in the risk of breast and colon cancers and ladies who use bisphosphonates had about one half the risk of getting endometrial cancer compared with those who did not use them. Recently, it was reported that addition of bisphosphonates to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) could enhance the antitumor effect of EGFR-TKIs in patients with EGFR-mutant non-small-cell lung cancer and bone metastasis.

Keywords: Bisphosphonates, Multiple myeloma, Osteoclast, Pamidronate, Zoledronate.
with various biochemical processes in bone-resorbing osteoclasts after selective adsorption to mineral surfaces and subsequent internalization by osteoclasts [2]. Moreover, they can improve the biomechanical properties of bone in both normal animals and experimental models of osteoporosis if not given in excess [11].

The P-C-P part of the bisphosphonates is responsible for the robust affinity for binding to hydroxyapatite and permits for a number of diversities in structure on the basis of substitution in the R1 and R2 positions on the carbon atom [12]. Some experimental studies suggested that bisphosphonates may conserve osteocytes and osteoblasts against glucocorticoids-induced apoptosis [13]. Recent evidence proposed that the inhibition of osteocyte apoptosis by bisphosphonates is interposed through the conquering of connexion 43 hemichannels and brising of extracellular signal-regulated kinases [14,15].

Nitrogenous (N-containing) bisphosphonates include Alendronate, Ibandronate, Neridronate, Olpadronate, Pamidronate, Risedronate and Zoledronate while Non-nitrogenous (Non-N-containing) bisphosphonates include Clodronate, Etidronate and Thalidronate [16,17]. The non-nitrogenous bisphosphonates are metabolized within the cell to certain metabolites that substitute the terminal pyrophosphate moiety of adenosine triphosphate (ATP), producing a non-functional molecule that contends with ATP in the cellular energy metabolism. Duly, the osteoclasts commence apoptosis, leading to an overall bone resorption decrease [18]. Whereas, nitrogen containing bisphosphonates are suggested to restrain osteoclast activity by blocking the enzyme farnesyl diphosphate synthase in the HMG-CoA reductase pathway [19].

The clinical employment of bisphosphonates has dramatically grown during the past 3 decades especially for osteoporosis. The Food and Drug Administration's approval of pamidronate in 1995 for the remediation of normocalcemic patients with myeloma and in 1996 for women who suffered from osteolytic lesions due to metastatic breast cancer was followed by widespread use of pamidronate in patients with cancers that encompass bone. Hence, it was suggested that N-containing bisphosphonate, pamidronate, diminishes the frequency of skeletal-related events in patients with breast cancer or myeloma [20].

Randomized clinical trials evaluated the role of bisphosphonate adjuvant therapy in cancer are still in progress. In vitro and in vivo initial studies proposed that bisphosphonates play direct and indirect roles as antitumor drugs. Interestingly, some clinical data confirmed these conclusions in cancer patients with bone metastasis especially breast cancer [21-23].

Although, results from clinical trials assaying the anticancer efficiency of bisphosphonates have been conflicting, they generally uphold a small absolute improvement in overall survival, with the largest treatment impact on diminishing the bone metastasis recurrence [24]. Nevertheless, Vale et al. [25] showed that in prostate cancer with locally advanced disease, there is no evidence of survival benefits from bisphosphonates addition. However, treatment with bisphosphonates was previously indicated in men with prostate cancer who were castrated or received gonadotropin releasing hormone agonists and was at risk of osteoporosis [26]. Contrastingly, some preclinical studies had showed that bisphosphonates exhibit direct and indirect anticancer activities in patients with early breast cancer or symptomatic multiple myeloma exhibiting disease-free survival and overall survival benefits [27].

In a randomized study, prostate cancer patients were treated with these gonadotropin releasing hormone agonists, alone or with pamidronate. The pamidronate-treated patients did not lose bone mineral density, whereas patients treated with the gonadotropin-releasing hormone agonist alone experienced significant bone loss [28]. Solid tumors (lung cancer, breast cancer, prostate cancer) and multiple myeloma are liable to develop bone metastasis. In the bone marrow, tumor cells do not devastate bone rather than altering the functions of osteoclasts and osteoblasts, and hijacking advent signals from the bone matrix. Thus, tumor cells block bone formation and consolidate bone resorption leading to skeletal destruction and subsequent occurrence of skeletal events [29]. These skeletal events can be lethal and have great impact on patients by causing hypercalcemia, pathological fractures, spinal cord compression and mobility loss [30].

Owing to their sturdy anti-resorptive efficacy, bisphosphonates (especially N-containing bisphosphonates) are therefore used to treat malignant bone diseases and delay skeletal events associated with bone metastasis [31]. Thence, there may be a growing justification for the use of bisphosphonates than has previously been considered.

Concordantly, some epidemiological studies concluded that current use of bisphosphonates in healthy postmenopausal ladies to manage osteoporosis was correlated with a 30% reduction in the risk of breast and colon cancers. These conclusions highlight the significance of identifying mechanisms that are responsible for the anticancer efficacy of some bisphosphonates like zoledronate and clodronate against breast cancer under estrogen indigence. Understanding these distinct mechanisms beyond the fact that zoledronate improved cancer-related outcomes in patients with newly diagnosed multiple myeloma as well as in patients with breast cancer, will assist to better recognize patients who could get benefits from treatment with bisphosphonate [26].

Some investigators reported a significant reduction (32 vs. 63; P<0.005) in the total number of bone metastases in stage IV breast cancer patients without skeletal metastases after placebo administration of 1,600 mg clodronate for 3 years [32]. Due to the poor oral bioavailability of pamidronate, a similar trial of its oral administration failed to emphasize these findings [33].

There is growing preclinical evidence suggesting that adjuvant protocols utilizing N-containing bisphosphonates in combination therapy results in increased antitumor effects against breast tumors and improved survival [34]. Moreover, a recent proposal suggested that ladies who use bisphosphonates had about one half the risk of getting endometrial cancer compared with ladies who did not use
these medications. Alford et al. [35] assessed whether bisphosphonates might help prevent endometrial cancer. The researchers evaluated information from the National Cancer Institute’s PLCO (Prostate, Lung, Colorectal and Ovarian) Screening Trial, which included questionnaires about bone medication use. Data were analyzed only for bisphosphonates that contain nitrogen, which are known to have strong anticancer activity. The study included 29,254 women. After factors such as age, race, history of hormone therapy use, smoking status and body mass index had been taken into account, bisphosphonate users were half as likely to develop endometrial cancer.

Zhang et al. [36] reported that epidermal growth factor receptor (EGFR) mutation was the significant independent prognostic factor for overall survival and the addition of bisphosphonates to epidermal growth factor receptor -tyrosine kinase inhibitors (EGFR-TKIs) could enhance the antitumor effect of EGFR-TKIs in patients with EGFR-mutant non-small-cell lung cancer and bone metastasis.

**Conclusion**

Bisphosphonates are anti-resorptive drugs that widely utilized in osteoporosis, Paget’s disease, multiple myeloma, cancer-induced hypercalcemia, and bony metastases to suppress osteoclastic bone resorption. Due to their powerful anti-resorptive efficacy, bisphosphonates (especially N-containing bisphosphonates) are therefore used to treat malignant bone diseases and delay skeletal events associated with bone metastasis. There is a strong evidence that bisphosphonates exhibit direct and indirect antitumor activities in patients with prostate cancer, early breast cancer or symptomatic multiple myeloma exhibiting some overall survival benefits. Concordantly, adjuvant protocols utilizing N-containing bisphosphonates in combination therapy resulted in increased antitumor effects against breast tumors and improved survival.

**References**


*Correspondence to: Mohammed Helmy Faris Shalayel College of Medicine Najran University Saudi Arabia Tel: +966-541476862 E-mail: drmhfs@hotmail.com